{"entity":{"type":"insider","cik":"0001706140","url":"/insider/0001706140","json_url":"/insider/0001706140.json","name":"Boyd Steven","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":1297,"n_filings":196,"first":"2017-05-09","last":"2023-06-28","span_basis":"filed_date"},"name_variants":[{"name":"Boyd Steven","source":"filing","n_filings":196,"first_seen":"2017-05-09","last_seen":"2023-06-28"}],"transactions":[{"id":8422075,"accession":"0000899243-23-016659","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-23-016659","line_url":"/filing/0000899243-23-016659#line-2","is_derivative":false,"issuer_cik":"0001534120","issuer_name":"Avalo Therapeutics, Inc.","issuer_ticker":"AVTX","issuer_name_source":null,"issuer_url":"/issuer/0001534120","owner_cik":null,"owner_name":"Boyd Steven; Armistice Capital Master Fund Ltd.; ARMISTICE CAPITAL, LLC","owner_display_name":"Boyd Steven","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":937404.0,"shares_display":"937,404","price_per_share":0.5194,"price_display":"0.52","price_state":"stated","total_value":486887.6376,"total_display":"486,887.64","total_whole":"486,888","shares_owned_after":731458.0,"shares_owned_after_display":"731,458","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-06-27","filed_date":"2023-06-28","scope":"insider"},{"id":8422069,"accession":"0000899243-23-016659","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-23-016659","line_url":"/filing/0000899243-23-016659#line-1","is_derivative":false,"issuer_cik":"0001534120","issuer_name":"Avalo Therapeutics, Inc.","issuer_ticker":"AVTX","issuer_name_source":null,"issuer_url":"/issuer/0001534120","owner_cik":null,"owner_name":"Boyd Steven; Armistice Capital Master Fund Ltd.; ARMISTICE CAPITAL, LLC","owner_display_name":"Boyd Steven","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2746138.0,"shares_display":"2,746,138","price_per_share":0.6125,"price_display":"0.61","price_state":"stated","total_value":1682009.525,"total_display":"1,682,009.52","total_whole":"1,682,010","shares_owned_after":1668862.0,"shares_owned_after_display":"1,668,862","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-06-26","filed_date":"2023-06-28","scope":"insider"},{"id":8619981,"accession":"0000899243-23-004412","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-23-004412","line_url":"/filing/0000899243-23-004412#line-2","is_derivative":false,"issuer_cik":"0001534120","issuer_name":"Avalo Therapeutics, Inc.","issuer_ticker":"AVTX","issuer_name_source":null,"issuer_url":"/issuer/0001534120","owner_cik":null,"owner_name":"Armistice Capital Master Fund Ltd.; Boyd Steven; ARMISTICE CAPITAL, LLC","owner_display_name":"Armistice Capital Master Fund Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":450000.0,"shares_display":"450,000","price_per_share":null,"price_display":null,"price_state":"not-stated","total_value":null,"total_display":null,"total_whole":null,"shares_owned_after":4415000.0,"shares_owned_after_display":"4,415,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-02-07","filed_date":"2023-02-09","scope":"insider"},{"id":6117139,"accession":"0000899243-22-010904","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-22-010904","line_url":"/filing/0000899243-22-010904#line-3","is_derivative":false,"issuer_cik":"0001534120","issuer_name":"Avalo Therapeutics, Inc.","issuer_ticker":"AVTX","issuer_name_source":null,"issuer_url":"/issuer/0001534120","owner_cik":null,"owner_name":"ARMISTICE CAPITAL, LLC; Boyd Steven; Armistice Capital Master Fund Ltd.","owner_display_name":"ARMISTICE CAPITAL, LLC","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":100000.0,"shares_display":"100,000","price_per_share":0.6494,"price_display":"0.65","price_state":"stated","total_value":64940.0,"total_display":"64,940.00","total_whole":"64,940","shares_owned_after":47576000.0,"shares_owned_after_display":"47,576,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-03-14","filed_date":"2022-03-14","scope":"insider"},{"id":6117137,"accession":"0000899243-22-010904","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-22-010904","line_url":"/filing/0000899243-22-010904#line-2","is_derivative":false,"issuer_cik":"0001534120","issuer_name":"Avalo Therapeutics, Inc.","issuer_ticker":"AVTX","issuer_name_source":null,"issuer_url":"/issuer/0001534120","owner_cik":null,"owner_name":"ARMISTICE CAPITAL, LLC; Boyd Steven; Armistice Capital Master Fund Ltd.","owner_display_name":"ARMISTICE CAPITAL, LLC","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":100000.0,"shares_display":"100,000","price_per_share":0.6878,"price_display":"0.69","price_state":"stated","total_value":68780.0,"total_display":"68,780.00","total_whole":"68,780","shares_owned_after":47476000.0,"shares_owned_after_display":"47,476,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-03-11","filed_date":"2022-03-14","scope":"insider"},{"id":6117131,"accession":"0000899243-22-010904","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-22-010904","line_url":"/filing/0000899243-22-010904#line-1","is_derivative":false,"issuer_cik":"0001534120","issuer_name":"Avalo Therapeutics, Inc.","issuer_ticker":"AVTX","issuer_name_source":null,"issuer_url":"/issuer/0001534120","owner_cik":null,"owner_name":"ARMISTICE CAPITAL, LLC; Boyd Steven; Armistice Capital Master Fund Ltd.","owner_display_name":"ARMISTICE CAPITAL, LLC","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":26000.0,"shares_display":"26,000","price_per_share":0.701,"price_display":"0.70","price_state":"stated","total_value":18226.0,"total_display":"18,226.00","total_whole":"18,226","shares_owned_after":47376000.0,"shares_owned_after_display":"47,376,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-03-10","filed_date":"2022-03-14","scope":"insider"},{"id":6973604,"accession":"0000899243-22-009744","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-22-009744","line_url":"/filing/0000899243-22-009744#line-3","is_derivative":false,"issuer_cik":"0001534120","issuer_name":"Avalo Therapeutics, Inc.","issuer_ticker":"AVTX","issuer_name_source":null,"issuer_url":"/issuer/0001534120","owner_cik":null,"owner_name":"Armistice Capital Master Fund Ltd.; ARMISTICE CAPITAL, LLC; Boyd Steven","owner_display_name":"Armistice Capital Master Fund Ltd.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":325000.0,"shares_display":"325,000","price_per_share":0.6564,"price_display":"0.66","price_state":"stated","total_value":213330.0,"total_display":"213,330.00","total_whole":"213,330","shares_owned_after":47350000.0,"shares_owned_after_display":"47,350,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-03-07","filed_date":"2022-03-07","scope":"insider"},{"id":6973602,"accession":"0000899243-22-009744","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-22-009744","line_url":"/filing/0000899243-22-009744#line-2","is_derivative":false,"issuer_cik":"0001534120","issuer_name":"Avalo Therapeutics, Inc.","issuer_ticker":"AVTX","issuer_name_source":null,"issuer_url":"/issuer/0001534120","owner_cik":null,"owner_name":"Armistice Capital Master Fund Ltd.; ARMISTICE CAPITAL, LLC; Boyd Steven","owner_display_name":"Armistice Capital Master Fund Ltd.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":135000.0,"shares_display":"135,000","price_per_share":0.7045,"price_display":"0.70","price_state":"stated","total_value":95107.5,"total_display":"95,107.50","total_whole":"95,108","shares_owned_after":47025000.0,"shares_owned_after_display":"47,025,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-03-04","filed_date":"2022-03-07","scope":"insider"},{"id":6973600,"accession":"0000899243-22-009744","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-22-009744","line_url":"/filing/0000899243-22-009744#line-1","is_derivative":false,"issuer_cik":"0001534120","issuer_name":"Avalo Therapeutics, Inc.","issuer_ticker":"AVTX","issuer_name_source":null,"issuer_url":"/issuer/0001534120","owner_cik":null,"owner_name":"Armistice Capital Master Fund Ltd.; ARMISTICE CAPITAL, LLC; Boyd Steven","owner_display_name":"Armistice Capital Master Fund Ltd.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":50000.0,"shares_display":"50,000","price_per_share":0.7139,"price_display":"0.71","price_state":"stated","total_value":35695.0,"total_display":"35,695.00","total_whole":"35,695","shares_owned_after":46890000.0,"shares_owned_after_display":"46,890,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-03-03","filed_date":"2022-03-07","scope":"insider"},{"id":6117052,"accession":"0000899243-22-008145","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-22-008145","line_url":"/filing/0000899243-22-008145#line-2","is_derivative":false,"issuer_cik":"0001534120","issuer_name":"Avalo Therapeutics, Inc.","issuer_ticker":"AVTX","issuer_name_source":null,"issuer_url":"/issuer/0001534120","owner_cik":null,"owner_name":"Armistice Capital Master Fund Ltd.; ARMISTICE CAPITAL, LLC; Boyd Steven","owner_display_name":"Armistice Capital Master Fund Ltd.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":40000.0,"shares_display":"40,000","price_per_share":0.7929,"price_display":"0.79","price_state":"stated","total_value":31716.0,"total_display":"31,716.00","total_whole":"31,716","shares_owned_after":46840000.0,"shares_owned_after_display":"46,840,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-02-25","filed_date":"2022-02-28","scope":"insider"},{"id":6117048,"accession":"0000899243-22-008145","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-22-008145","line_url":"/filing/0000899243-22-008145#line-1","is_derivative":false,"issuer_cik":"0001534120","issuer_name":"Avalo Therapeutics, Inc.","issuer_ticker":"AVTX","issuer_name_source":null,"issuer_url":"/issuer/0001534120","owner_cik":null,"owner_name":"Armistice Capital Master Fund Ltd.; ARMISTICE CAPITAL, LLC; Boyd Steven","owner_display_name":"Armistice Capital Master Fund Ltd.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":100000.0,"shares_display":"100,000","price_per_share":0.8009,"price_display":"0.80","price_state":"stated","total_value":80090.0,"total_display":"80,090.00","total_whole":"80,090","shares_owned_after":46800000.0,"shares_owned_after_display":"46,800,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-02-24","filed_date":"2022-02-28","scope":"insider"},{"id":6669866,"accession":"0000899243-22-007249","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-22-007249","line_url":"/filing/0000899243-22-007249#line-3","is_derivative":false,"issuer_cik":"0001534120","issuer_name":"Avalo Therapeutics, Inc.","issuer_ticker":"AVTX","issuer_name_source":null,"issuer_url":"/issuer/0001534120","owner_cik":null,"owner_name":"ARMISTICE CAPITAL, LLC; Boyd Steven; Armistice Capital Master Fund Ltd.","owner_display_name":"ARMISTICE CAPITAL, LLC","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":83000.0,"shares_display":"83,000","price_per_share":0.772,"price_display":"0.77","price_state":"stated","total_value":64076.0,"total_display":"64,076.00","total_whole":"64,076","shares_owned_after":46700000.0,"shares_owned_after_display":"46,700,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-02-22","filed_date":"2022-02-22","scope":"insider"},{"id":6669864,"accession":"0000899243-22-007249","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-22-007249","line_url":"/filing/0000899243-22-007249#line-2","is_derivative":false,"issuer_cik":"0001534120","issuer_name":"Avalo Therapeutics, Inc.","issuer_ticker":"AVTX","issuer_name_source":null,"issuer_url":"/issuer/0001534120","owner_cik":null,"owner_name":"ARMISTICE CAPITAL, LLC; Boyd Steven; Armistice Capital Master Fund Ltd.","owner_display_name":"ARMISTICE CAPITAL, LLC","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":55000.0,"shares_display":"55,000","price_per_share":0.8225,"price_display":"0.82","price_state":"stated","total_value":45237.5,"total_display":"45,237.50","total_whole":"45,238","shares_owned_after":46617000.0,"shares_owned_after_display":"46,617,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-02-18","filed_date":"2022-02-22","scope":"insider"},{"id":6669862,"accession":"0000899243-22-007249","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-22-007249","line_url":"/filing/0000899243-22-007249#line-1","is_derivative":false,"issuer_cik":"0001534120","issuer_name":"Avalo Therapeutics, Inc.","issuer_ticker":"AVTX","issuer_name_source":null,"issuer_url":"/issuer/0001534120","owner_cik":null,"owner_name":"ARMISTICE CAPITAL, LLC; Boyd Steven; Armistice Capital Master Fund Ltd.","owner_display_name":"ARMISTICE CAPITAL, LLC","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":150000.0,"shares_display":"150,000","price_per_share":0.815,"price_display":"0.82","price_state":"stated","total_value":122250.0,"total_display":"122,250.00","total_whole":"122,250","shares_owned_after":46562000.0,"shares_owned_after_display":"46,562,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-02-17","filed_date":"2022-02-22","scope":"insider"},{"id":6973329,"accession":"0000899243-22-002693","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-22-002693","line_url":"/filing/0000899243-22-002693#line-3","is_derivative":false,"issuer_cik":"0001534120","issuer_name":"Avalo Therapeutics, Inc.","issuer_ticker":"AVTX","issuer_name_source":null,"issuer_url":"/issuer/0001534120","owner_cik":null,"owner_name":"Armistice Capital Master Fund Ltd.; Boyd Steven; ARMISTICE CAPITAL, LLC","owner_display_name":"Armistice Capital Master Fund Ltd.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":12000.0,"shares_display":"12,000","price_per_share":0.8507,"price_display":"0.85","price_state":"stated","total_value":10208.4,"total_display":"10,208.40","total_whole":"10,208","shares_owned_after":46412000.0,"shares_owned_after_display":"46,412,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-01-20","filed_date":"2022-01-20","scope":"insider"},{"id":6973326,"accession":"0000899243-22-002693","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-22-002693","line_url":"/filing/0000899243-22-002693#line-2","is_derivative":false,"issuer_cik":"0001534120","issuer_name":"Avalo Therapeutics, Inc.","issuer_ticker":"AVTX","issuer_name_source":null,"issuer_url":"/issuer/0001534120","owner_cik":null,"owner_name":"Armistice Capital Master Fund Ltd.; Boyd Steven; ARMISTICE CAPITAL, LLC","owner_display_name":"Armistice Capital Master Fund Ltd.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":93700.0,"shares_display":"93,700","price_per_share":0.8757,"price_display":"0.88","price_state":"stated","total_value":82053.09,"total_display":"82,053.09","total_whole":"82,053","shares_owned_after":46400000.0,"shares_owned_after_display":"46,400,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-01-19","filed_date":"2022-01-20","scope":"insider"},{"id":6973323,"accession":"0000899243-22-002693","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-22-002693","line_url":"/filing/0000899243-22-002693#line-1","is_derivative":false,"issuer_cik":"0001534120","issuer_name":"Avalo Therapeutics, Inc.","issuer_ticker":"AVTX","issuer_name_source":null,"issuer_url":"/issuer/0001534120","owner_cik":null,"owner_name":"Armistice Capital Master Fund Ltd.; Boyd Steven; ARMISTICE CAPITAL, LLC","owner_display_name":"Armistice Capital Master Fund Ltd.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":206300.0,"shares_display":"206,300","price_per_share":0.8833,"price_display":"0.88","price_state":"stated","total_value":182224.79,"total_display":"182,224.79","total_whole":"182,225","shares_owned_after":46306300.0,"shares_owned_after_display":"46,306,300","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-01-18","filed_date":"2022-01-20","scope":"insider"},{"id":6199566,"accession":"0000899243-22-002025","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-22-002025","line_url":"/filing/0000899243-22-002025#line-3","is_derivative":false,"issuer_cik":"0001534120","issuer_name":"Avalo Therapeutics, Inc.","issuer_ticker":"AVTX","issuer_name_source":null,"issuer_url":"/issuer/0001534120","owner_cik":null,"owner_name":"ARMISTICE CAPITAL, LLC; Armistice Capital Master Fund Ltd.; Boyd Steven","owner_display_name":"ARMISTICE CAPITAL, LLC","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":85000.0,"shares_display":"85,000","price_per_share":0.9291,"price_display":"0.93","price_state":"stated","total_value":78973.5,"total_display":"78,973.50","total_whole":"78,974","shares_owned_after":46100000.0,"shares_owned_after_display":"46,100,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-01-14","filed_date":"2022-01-14","scope":"insider"},{"id":6199563,"accession":"0000899243-22-002025","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-22-002025","line_url":"/filing/0000899243-22-002025#line-2","is_derivative":false,"issuer_cik":"0001534120","issuer_name":"Avalo Therapeutics, Inc.","issuer_ticker":"AVTX","issuer_name_source":null,"issuer_url":"/issuer/0001534120","owner_cik":null,"owner_name":"ARMISTICE CAPITAL, LLC; Armistice Capital Master Fund Ltd.; Boyd Steven","owner_display_name":"ARMISTICE CAPITAL, LLC","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":312700.0,"shares_display":"312,700","price_per_share":1.0042,"price_display":"1.00","price_state":"stated","total_value":314013.34,"total_display":"314,013.34","total_whole":"314,013","shares_owned_after":46015000.0,"shares_owned_after_display":"46,015,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-01-13","filed_date":"2022-01-14","scope":"insider"},{"id":6199557,"accession":"0000899243-22-002025","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-22-002025","line_url":"/filing/0000899243-22-002025#line-1","is_derivative":false,"issuer_cik":"0001534120","issuer_name":"Avalo Therapeutics, Inc.","issuer_ticker":"AVTX","issuer_name_source":null,"issuer_url":"/issuer/0001534120","owner_cik":null,"owner_name":"ARMISTICE CAPITAL, LLC; Armistice Capital Master Fund Ltd.; Boyd Steven","owner_display_name":"ARMISTICE CAPITAL, LLC","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":57300.0,"shares_display":"57,300","price_per_share":1.0433,"price_display":"1.04","price_state":"stated","total_value":59781.09,"total_display":"59,781.09","total_whole":"59,781","shares_owned_after":45702300.0,"shares_owned_after_display":"45,702,300","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-01-12","filed_date":"2022-01-14","scope":"insider"},{"id":6166236,"accession":"0000899243-22-001618","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-22-001618","line_url":"/filing/0000899243-22-001618#line-3","is_derivative":false,"issuer_cik":"0001534120","issuer_name":"Avalo Therapeutics, Inc.","issuer_ticker":"AVTX","issuer_name_source":null,"issuer_url":"/issuer/0001534120","owner_cik":null,"owner_name":"ARMISTICE CAPITAL, LLC; Boyd Steven; Armistice Capital Master Fund Ltd.","owner_display_name":"ARMISTICE CAPITAL, LLC","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":16003.0,"shares_display":"16,003","price_per_share":0.9587,"price_display":"0.96","price_state":"stated","total_value":15342.0761,"total_display":"15,342.08","total_whole":"15,342","shares_owned_after":45645000.0,"shares_owned_after_display":"45,645,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-01-11","filed_date":"2022-01-11","scope":"insider"},{"id":6166233,"accession":"0000899243-22-001618","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-22-001618","line_url":"/filing/0000899243-22-001618#line-2","is_derivative":false,"issuer_cik":"0001534120","issuer_name":"Avalo Therapeutics, Inc.","issuer_ticker":"AVTX","issuer_name_source":null,"issuer_url":"/issuer/0001534120","owner_cik":null,"owner_name":"ARMISTICE CAPITAL, LLC; Boyd Steven; Armistice Capital Master Fund Ltd.","owner_display_name":"ARMISTICE CAPITAL, LLC","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":491097.0,"shares_display":"491,097","price_per_share":0.9868,"price_display":"0.99","price_state":"stated","total_value":484614.5196,"total_display":"484,614.52","total_whole":"484,615","shares_owned_after":45628997.0,"shares_owned_after_display":"45,628,997","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-01-10","filed_date":"2022-01-11","scope":"insider"},{"id":6166230,"accession":"0000899243-22-001618","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-22-001618","line_url":"/filing/0000899243-22-001618#line-1","is_derivative":false,"issuer_cik":"0001534120","issuer_name":"Avalo Therapeutics, Inc.","issuer_ticker":"AVTX","issuer_name_source":null,"issuer_url":"/issuer/0001534120","owner_cik":null,"owner_name":"ARMISTICE CAPITAL, LLC; Boyd Steven; Armistice Capital Master Fund Ltd.","owner_display_name":"ARMISTICE CAPITAL, LLC","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":137900.0,"shares_display":"137,900","price_per_share":1.0368,"price_display":"1.04","price_state":"stated","total_value":142974.72,"total_display":"142,974.72","total_whole":"142,975","shares_owned_after":45137900.0,"shares_owned_after_display":"45,137,900","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-01-07","filed_date":"2022-01-11","scope":"insider"},{"id":5364452,"accession":"0000899243-21-036402","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-21-036402","line_url":"/filing/0000899243-21-036402#line-3","is_derivative":false,"issuer_cik":"0001534120","issuer_name":"Avalo Therapeutics, Inc.","issuer_ticker":"AVTX","issuer_name_source":null,"issuer_url":"/issuer/0001534120","owner_cik":null,"owner_name":"Boyd Steven; ARMISTICE CAPITAL, LLC; Armistice Capital Master Fund Ltd.","owner_display_name":"Boyd Steven","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5454545.0,"shares_display":"5,454,545","price_per_share":2.2,"price_display":"2.20","price_state":"stated","total_value":11999999.0,"total_display":"11,999,999.00","total_whole":"11,999,999","shares_owned_after":45000000.0,"shares_owned_after_display":"45,000,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-09-17","filed_date":"2021-09-17","scope":"insider"},{"id":5364442,"accession":"0000899243-21-036402","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-21-036402","line_url":"/filing/0000899243-21-036402#line-2","is_derivative":false,"issuer_cik":"0001534120","issuer_name":"Avalo Therapeutics, Inc.","issuer_ticker":"AVTX","issuer_name_source":null,"issuer_url":"/issuer/0001534120","owner_cik":null,"owner_name":"Boyd Steven; ARMISTICE CAPITAL, LLC; Armistice Capital Master Fund Ltd.","owner_display_name":"Boyd Steven","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":150000.0,"shares_display":"150,000","price_per_share":2.2797,"price_display":"2.28","price_state":"stated","total_value":341955.0,"total_display":"341,955.00","total_whole":"341,955","shares_owned_after":39545455.0,"shares_owned_after_display":"39,545,455","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-09-16","filed_date":"2021-09-17","scope":"insider"},{"id":5364438,"accession":"0000899243-21-036402","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-21-036402","line_url":"/filing/0000899243-21-036402#line-1","is_derivative":false,"issuer_cik":"0001534120","issuer_name":"Avalo Therapeutics, Inc.","issuer_ticker":"AVTX","issuer_name_source":null,"issuer_url":"/issuer/0001534120","owner_cik":null,"owner_name":"Boyd Steven; ARMISTICE CAPITAL, LLC; Armistice Capital Master Fund Ltd.","owner_display_name":"Boyd Steven","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":95455.0,"shares_display":"95,455","price_per_share":2.2623,"price_display":"2.26","price_state":"stated","total_value":215947.8465,"total_display":"215,947.85","total_whole":"215,948","shares_owned_after":39395455.0,"shares_owned_after_display":"39,395,455","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-09-15","filed_date":"2021-09-17","scope":"insider"},{"id":4306220,"accession":"0000899243-21-033505","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-21-033505","line_url":"/filing/0000899243-21-033505#line-2","is_derivative":false,"issuer_cik":"0001534120","issuer_name":"Cerecor Inc.","issuer_ticker":"CERC","issuer_name_source":null,"issuer_url":"/issuer/0001534120","owner_cik":null,"owner_name":"Armistice Capital Master Fund Ltd.; ARMISTICE CAPITAL, LLC; Boyd Steven","owner_display_name":"Armistice Capital Master Fund Ltd.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":20000.0,"shares_display":"20,000","price_per_share":2.7775,"price_display":"2.78","price_state":"stated","total_value":55550.0,"total_display":"55,550.00","total_whole":"55,550","shares_owned_after":39300000.0,"shares_owned_after_display":"39,300,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-08-18","filed_date":"2021-08-18","scope":"insider"},{"id":4306214,"accession":"0000899243-21-033505","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-21-033505","line_url":"/filing/0000899243-21-033505#line-1","is_derivative":false,"issuer_cik":"0001534120","issuer_name":"Cerecor Inc.","issuer_ticker":"CERC","issuer_name_source":null,"issuer_url":"/issuer/0001534120","owner_cik":null,"owner_name":"Armistice Capital Master Fund Ltd.; ARMISTICE CAPITAL, LLC; Boyd Steven","owner_display_name":"Armistice Capital Master Fund Ltd.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":30000.0,"shares_display":"30,000","price_per_share":2.7546,"price_display":"2.75","price_state":"stated","total_value":82638.0,"total_display":"82,638.00","total_whole":"82,638","shares_owned_after":39280000.0,"shares_owned_after_display":"39,280,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-08-16","filed_date":"2021-08-18","scope":"insider"},{"id":5497060,"accession":"0001567619-21-014631","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001567619-21-014631","line_url":"/filing/0001567619-21-014631#line-3","is_derivative":false,"issuer_cik":"0001534120","issuer_name":"Cerecor Inc.","issuer_ticker":"CERC","issuer_name_source":null,"issuer_url":"/issuer/0001534120","owner_cik":null,"owner_name":"Armistice Capital Master Fund Ltd.; ARMISTICE CAPITAL, LLC; Boyd Steven","owner_display_name":"Armistice Capital Master Fund Ltd.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":25000.0,"shares_display":"25,000","price_per_share":2.8252,"price_display":"2.83","price_state":"stated","total_value":70630.0,"total_display":"70,630.00","total_whole":"70,630","shares_owned_after":39250000.0,"shares_owned_after_display":"39,250,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-08-06","filed_date":"2021-08-06","scope":"insider"},{"id":5497057,"accession":"0001567619-21-014631","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001567619-21-014631","line_url":"/filing/0001567619-21-014631#line-2","is_derivative":false,"issuer_cik":"0001534120","issuer_name":"Cerecor Inc.","issuer_ticker":"CERC","issuer_name_source":null,"issuer_url":"/issuer/0001534120","owner_cik":null,"owner_name":"Armistice Capital Master Fund Ltd.; ARMISTICE CAPITAL, LLC; Boyd Steven","owner_display_name":"Armistice Capital Master Fund Ltd.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":25000.0,"shares_display":"25,000","price_per_share":2.7718,"price_display":"2.77","price_state":"stated","total_value":69295.0,"total_display":"69,295.00","total_whole":"69,295","shares_owned_after":39225000.0,"shares_owned_after_display":"39,225,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-08-05","filed_date":"2021-08-06","scope":"insider"},{"id":5497054,"accession":"0001567619-21-014631","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001567619-21-014631","line_url":"/filing/0001567619-21-014631#line-1","is_derivative":false,"issuer_cik":"0001534120","issuer_name":"Cerecor Inc.","issuer_ticker":"CERC","issuer_name_source":null,"issuer_url":"/issuer/0001534120","owner_cik":null,"owner_name":"Armistice Capital Master Fund Ltd.; ARMISTICE CAPITAL, LLC; Boyd Steven","owner_display_name":"Armistice Capital Master Fund Ltd.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":100000.0,"shares_display":"100,000","price_per_share":2.6859,"price_display":"2.69","price_state":"stated","total_value":268590.0,"total_display":"268,590.00","total_whole":"268,590","shares_owned_after":39200000.0,"shares_owned_after_display":"39,200,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-08-04","filed_date":"2021-08-06","scope":"insider"},{"id":5227614,"accession":"0001567619-21-014361","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001567619-21-014361","line_url":"/filing/0001567619-21-014361#line-2","is_derivative":false,"issuer_cik":"0001372514","issuer_name":"EYEGATE PHARMACEUTICALS INC","issuer_ticker":"EYEG","issuer_name_source":null,"issuer_url":"/issuer/0001372514","owner_cik":null,"owner_name":"ARMISTICE CAPITAL, LLC; Armistice Capital Master Fund Ltd.; Boyd Steven","owner_display_name":"ARMISTICE CAPITAL, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":192775.0,"shares_display":"192,775","price_per_share":2.402,"price_display":"2.40","price_state":"stated","total_value":463045.55,"total_display":"463,045.55","total_whole":"463,046","shares_owned_after":785000.0,"shares_owned_after_display":"785,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-08-02","filed_date":"2021-08-03","scope":"insider"},{"id":5227607,"accession":"0001567619-21-014361","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001567619-21-014361","line_url":"/filing/0001567619-21-014361#line-1","is_derivative":false,"issuer_cik":"0001372514","issuer_name":"EYEGATE PHARMACEUTICALS INC","issuer_ticker":"EYEG","issuer_name_source":null,"issuer_url":"/issuer/0001372514","owner_cik":null,"owner_name":"ARMISTICE CAPITAL, LLC; Armistice Capital Master Fund Ltd.; Boyd Steven","owner_display_name":"ARMISTICE CAPITAL, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":68188.0,"shares_display":"68,188","price_per_share":2.692,"price_display":"2.69","price_state":"stated","total_value":183562.096,"total_display":"183,562.10","total_whole":"183,562","shares_owned_after":977775.0,"shares_owned_after_display":"977,775","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-07-30","filed_date":"2021-08-03","scope":"insider"},{"id":4266782,"accession":"0000899243-21-030722","txn_seq":8,"anchor":"line-8","filing_url":"/filing/0000899243-21-030722","line_url":"/filing/0000899243-21-030722#line-8","is_derivative":false,"issuer_cik":"0001372514","issuer_name":"EYEGATE PHARMACEUTICALS INC","issuer_ticker":"EYEG","issuer_name_source":null,"issuer_url":"/issuer/0001372514","owner_cik":null,"owner_name":"Armistice Capital Master Fund Ltd.; Boyd Steven; ARMISTICE CAPITAL, LLC","owner_display_name":"Armistice Capital Master Fund Ltd.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":400000.0,"shares_display":"400,000","price_per_share":3.0,"price_display":"3.00","price_state":"stated","total_value":1200000.0,"total_display":"1,200,000.00","total_whole":"1,200,000","shares_owned_after":1045963.0,"shares_owned_after_display":"1,045,963","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-07-29","filed_date":"2021-07-29","scope":"insider"},{"id":4266777,"accession":"0000899243-21-030722","txn_seq":7,"anchor":"line-7","filing_url":"/filing/0000899243-21-030722","line_url":"/filing/0000899243-21-030722#line-7","is_derivative":false,"issuer_cik":"0001372514","issuer_name":"EYEGATE PHARMACEUTICALS INC","issuer_ticker":"EYEG","issuer_name_source":null,"issuer_url":"/issuer/0001372514","owner_cik":null,"owner_name":"Armistice Capital Master Fund Ltd.; Boyd Steven; ARMISTICE CAPITAL, LLC","owner_display_name":"Armistice Capital Master Fund Ltd.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":375443.0,"shares_display":"375,443","price_per_share":3.2831,"price_display":"3.28","price_state":"stated","total_value":1232616.9133,"total_display":"1,232,616.91","total_whole":"1,232,617","shares_owned_after":1445963.0,"shares_owned_after_display":"1,445,963","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-07-28","filed_date":"2021-07-29","scope":"insider"},{"id":4266771,"accession":"0000899243-21-030722","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0000899243-21-030722","line_url":"/filing/0000899243-21-030722","is_derivative":false,"issuer_cik":"0001372514","issuer_name":"EYEGATE PHARMACEUTICALS INC","issuer_ticker":"EYEG","issuer_name_source":null,"issuer_url":"/issuer/0001372514","owner_cik":null,"owner_name":"Armistice Capital Master Fund Ltd.; Boyd Steven; ARMISTICE CAPITAL, LLC","owner_display_name":"Armistice Capital Master Fund Ltd.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2377695.0,"shares_display":"2,377,695","price_per_share":5.0947018430034126,"price_display":"5.09","price_state":"stated","total_value":12113647.0986,"total_display":"12,113,647.10","total_whole":"12,113,647","shares_owned_after":2935089.0,"shares_owned_after_display":"2,935,089","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-07-27","filed_date":"2021-07-29","scope":"insider","n_lines":5},{"id":5365932,"accession":"0000919574-21-004191","txn_seq":12,"anchor":"line-12","filing_url":"/filing/0000919574-21-004191","line_url":"/filing/0000919574-21-004191#line-12","is_derivative":false,"issuer_cik":"0001427570","issuer_name":"ReShape Lifesciences Inc.","issuer_ticker":"RSLS","issuer_name_source":null,"issuer_url":"/issuer/0001427570","owner_cik":null,"owner_name":"ARMISTICE CAPITAL, LLC; Boyd Steven","owner_display_name":"ARMISTICE CAPITAL, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":685583.0,"shares_display":"685,583","price_per_share":5.48,"price_display":"5.48","price_state":"stated","total_value":3756994.84,"total_display":"3,756,994.84","total_whole":"3,756,995","shares_owned_after":105873.0,"shares_owned_after_display":"105,873","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-06-18","filed_date":"2021-06-22","scope":"insider"},{"id":5365929,"accession":"0000919574-21-004191","txn_seq":11,"anchor":"line-11","filing_url":"/filing/0000919574-21-004191","line_url":"/filing/0000919574-21-004191#line-11","is_derivative":false,"issuer_cik":"0001427570","issuer_name":"ReShape Lifesciences Inc.","issuer_ticker":"RSLS","issuer_name_source":null,"issuer_url":"/issuer/0001427570","owner_cik":null,"owner_name":"ARMISTICE CAPITAL, LLC; Boyd Steven","owner_display_name":"ARMISTICE CAPITAL, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":0.0,"shares_display":"0","price_per_share":0.0,"price_display":null,"price_state":"not-stated","total_value":0.0,"total_display":null,"total_whole":null,"shares_owned_after":105873.0,"shares_owned_after_display":"105,873","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-06-18","filed_date":"2021-06-22","scope":"insider"},{"id":5365924,"accession":"0000919574-21-004191","txn_seq":10,"anchor":"line-10","filing_url":"/filing/0000919574-21-004191","line_url":"/filing/0000919574-21-004191#line-10","is_derivative":false,"issuer_cik":"0001427570","issuer_name":"ReShape Lifesciences Inc.","issuer_ticker":"RSLS","issuer_name_source":null,"issuer_url":"/issuer/0001427570","owner_cik":null,"owner_name":"ARMISTICE CAPITAL, LLC; Boyd Steven","owner_display_name":"ARMISTICE CAPITAL, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1024844.0,"shares_display":"1,024,844","price_per_share":6.2,"price_display":"6.20","price_state":"stated","total_value":6354032.8,"total_display":"6,354,032.80","total_whole":"6,354,033","shares_owned_after":872822.0,"shares_owned_after_display":"872,822","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-06-17","filed_date":"2021-06-22","scope":"insider"},{"id":5365922,"accession":"0000919574-21-004191","txn_seq":9,"anchor":"line-9","filing_url":"/filing/0000919574-21-004191","line_url":"/filing/0000919574-21-004191#line-9","is_derivative":false,"issuer_cik":"0001427570","issuer_name":"ReShape Lifesciences Inc.","issuer_ticker":"RSLS","issuer_name_source":null,"issuer_url":"/issuer/0001427570","owner_cik":null,"owner_name":"ARMISTICE CAPITAL, LLC; Boyd Steven","owner_display_name":"ARMISTICE CAPITAL, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":81366.0,"shares_display":"81,366","price_per_share":7.13,"price_display":"7.13","price_state":"stated","total_value":580139.58,"total_display":"580,139.58","total_whole":"580,140","shares_owned_after":791456.0,"shares_owned_after_display":"791,456","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-06-17","filed_date":"2021-06-22","scope":"insider"},{"id":5365919,"accession":"0000919574-21-004191","txn_seq":8,"anchor":"line-8","filing_url":"/filing/0000919574-21-004191","line_url":"/filing/0000919574-21-004191#line-8","is_derivative":false,"issuer_cik":"0001427570","issuer_name":"ReShape Lifesciences Inc.","issuer_ticker":"RSLS","issuer_name_source":null,"issuer_url":"/issuer/0001427570","owner_cik":null,"owner_name":"ARMISTICE CAPITAL, LLC; Boyd Steven","owner_display_name":"ARMISTICE CAPITAL, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":0.0,"shares_display":"0","price_per_share":0.0,"price_display":null,"price_state":"not-stated","total_value":0.0,"total_display":null,"total_whole":null,"shares_owned_after":872822.0,"shares_owned_after_display":"872,822","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-06-17","filed_date":"2021-06-22","scope":"insider"},{"id":5365915,"accession":"0000919574-21-004191","txn_seq":7,"anchor":"line-7","filing_url":"/filing/0000919574-21-004191","line_url":"/filing/0000919574-21-004191#line-7","is_derivative":false,"issuer_cik":"0001427570","issuer_name":"ReShape Lifesciences Inc.","issuer_ticker":"RSLS","issuer_name_source":null,"issuer_url":"/issuer/0001427570","owner_cik":null,"owner_name":"ARMISTICE CAPITAL, LLC; Boyd Steven","owner_display_name":"ARMISTICE CAPITAL, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":0.0,"shares_display":"0","price_per_share":0.0,"price_display":null,"price_state":"not-stated","total_value":0.0,"total_display":null,"total_whole":null,"shares_owned_after":791456.0,"shares_owned_after_display":"791,456","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-06-17","filed_date":"2021-06-22","scope":"insider"},{"id":5365913,"accession":"0000919574-21-004191","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0000919574-21-004191","line_url":"/filing/0000919574-21-004191#line-6","is_derivative":false,"issuer_cik":"0001427570","issuer_name":"ReShape Lifesciences Inc.","issuer_ticker":"RSLS","issuer_name_source":null,"issuer_url":"/issuer/0001427570","owner_cik":null,"owner_name":"ARMISTICE CAPITAL, LLC; Boyd Steven","owner_display_name":"ARMISTICE CAPITAL, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":388045.0,"shares_display":"388,045","price_per_share":6.52,"price_display":"6.52","price_state":"stated","total_value":2530053.4,"total_display":"2,530,053.40","total_whole":"2,530,053","shares_owned_after":2021297.0,"shares_owned_after_display":"2,021,297","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-06-16","filed_date":"2021-06-22","scope":"insider"},{"id":5365910,"accession":"0000919574-21-004191","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0000919574-21-004191","line_url":"/filing/0000919574-21-004191#line-5","is_derivative":false,"issuer_cik":"0001427570","issuer_name":"ReShape Lifesciences Inc.","issuer_ticker":"RSLS","issuer_name_source":null,"issuer_url":"/issuer/0001427570","owner_cik":null,"owner_name":"ARMISTICE CAPITAL, LLC; Boyd Steven","owner_display_name":"ARMISTICE CAPITAL, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":73591.0,"shares_display":"73,591","price_per_share":7.92,"price_display":"7.92","price_state":"stated","total_value":582840.72,"total_display":"582,840.72","total_whole":"582,841","shares_owned_after":1947706.0,"shares_owned_after_display":"1,947,706","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-06-16","filed_date":"2021-06-22","scope":"insider"},{"id":5365906,"accession":"0000919574-21-004191","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000919574-21-004191","line_url":"/filing/0000919574-21-004191#line-4","is_derivative":false,"issuer_cik":"0001427570","issuer_name":"ReShape Lifesciences Inc.","issuer_ticker":"RSLS","issuer_name_source":null,"issuer_url":"/issuer/0001427570","owner_cik":null,"owner_name":"ARMISTICE CAPITAL, LLC; Boyd Steven","owner_display_name":"ARMISTICE CAPITAL, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":50040.0,"shares_display":"50,040","price_per_share":8.52,"price_display":"8.52","price_state":"stated","total_value":426340.8,"total_display":"426,340.80","total_whole":"426,341","shares_owned_after":1897666.0,"shares_owned_after_display":"1,897,666","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-06-16","filed_date":"2021-06-22","scope":"insider"},{"id":5365898,"accession":"0000919574-21-004191","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000919574-21-004191","line_url":"/filing/0000919574-21-004191#line-3","is_derivative":false,"issuer_cik":"0001427570","issuer_name":"ReShape Lifesciences Inc.","issuer_ticker":"RSLS","issuer_name_source":null,"issuer_url":"/issuer/0001427570","owner_cik":null,"owner_name":"ARMISTICE CAPITAL, LLC; Boyd Steven","owner_display_name":"ARMISTICE CAPITAL, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":0.0,"shares_display":"0","price_per_share":0.0,"price_display":null,"price_state":"not-stated","total_value":0.0,"total_display":null,"total_whole":null,"shares_owned_after":2021297.0,"shares_owned_after_display":"2,021,297","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-06-16","filed_date":"2021-06-22","scope":"insider"}],"collapsed":true,"next_cursor":"2021-06-16|5365898","ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001534120","name":"Avalo Therapeutics, Inc.","url":"/issuer/0001534120","role":"Director, Ten percent owner","n_filings":74,"first_seen":"2017-05-09","last_seen":"2023-06-28"},{"type":"issuer","type_label":"ISSUER","cik":"0001372514","name":"EYEGATE PHARMACEUTICALS INC","url":"/issuer/0001372514","role":"Director, Ten percent owner","n_filings":16,"first_seen":"2018-04-17","last_seen":"2021-08-03"},{"type":"issuer","type_label":"ISSUER","cik":"0001427570","name":"ReShape Lifesciences Inc.","url":"/issuer/0001427570","role":"Ten percent owner","n_filings":1,"first_seen":"2021-06-22","last_seen":"2021-06-22"},{"type":"issuer","type_label":"ISSUER","cik":"0001385818","name":"AYTU BIOSCIENCE, INC","url":"/issuer/0001385818","role":"Director, Ten percent owner","n_filings":4,"first_seen":"2019-12-23","last_seen":"2020-12-15"},{"type":"issuer","type_label":"ISSUER","cik":"0001371217","name":"ReShape Lifesciences Inc.","url":"/issuer/0001371217","role":"Ten percent owner","n_filings":23,"first_seen":"2019-07-26","last_seen":"2020-12-04"},{"type":"issuer","type_label":"ISSUER","cik":"0000922247","name":"Cyclo Therapeutics, Inc.","url":"/issuer/0000922247","role":"Ten percent owner","n_filings":7,"first_seen":"2020-08-31","last_seen":"2020-10-01"},{"type":"issuer","type_label":"ISSUER","cik":"0000034956","name":"TENAX THERAPEUTICS, INC.","url":"/issuer/0000034956","role":"Director, Ten percent owner","n_filings":5,"first_seen":"2020-08-21","last_seen":"2020-09-09"},{"type":"issuer","type_label":"ISSUER","cik":"0000072444","name":"Vaxart, Inc.","url":"/issuer/0000072444","role":"Director, Ten percent owner","n_filings":13,"first_seen":"2019-09-30","last_seen":"2020-06-30"},{"type":"issuer","type_label":"ISSUER","cik":"0000792977","name":"AMAG PHARMACEUTICALS, INC.","url":"/issuer/0000792977","role":"Ten percent owner","n_filings":6,"first_seen":"2019-06-27","last_seen":"2020-03-18"},{"type":"issuer","type_label":"ISSUER","cik":"0001619250","name":"Valeritas Holdings Inc.","url":"/issuer/0001619250","role":"Ten percent owner","n_filings":11,"first_seen":"2018-11-20","last_seen":"2019-12-23"},{"type":"issuer","type_label":"ISSUER","cik":"0001130598","name":"Onconova Therapeutics, Inc.","url":"/issuer/0001130598","role":"Ten percent owner","n_filings":1,"first_seen":"2019-09-25","last_seen":"2019-09-25"},{"type":"issuer","type_label":"ISSUER","cik":"0001411879","name":"INNOVUS PHARMACEUTICALS, INC.","url":"/issuer/0001411879","role":"Ten percent owner","n_filings":1,"first_seen":"2019-09-18","last_seen":"2019-09-18"},{"type":"issuer","type_label":"ISSUER","cik":"0000949858","name":"ACHIEVE LIFE SCIENCES, INC.","url":"/issuer/0000949858","role":"Ten percent owner","n_filings":2,"first_seen":"2019-06-13","last_seen":"2019-06-13"},{"type":"issuer","type_label":"ISSUER","cik":"0001415301","name":"Del Frisco's Restaurant Group, Inc.","url":"/issuer/0001415301","role":"Director, Ten percent owner","n_filings":21,"first_seen":"2018-09-14","last_seen":"2019-06-06"},{"type":"issuer","type_label":"ISSUER","cik":"0001133818","name":"BIO-PATH HOLDINGS INC","url":"/issuer/0001133818","role":"Ten percent owner","n_filings":1,"first_seen":"2019-01-23","last_seen":"2019-01-23"},{"type":"issuer","type_label":"ISSUER","cik":"0000819050","name":"VICAL INC","url":"/issuer/0000819050","role":"Ten percent owner","n_filings":7,"first_seen":"2018-01-26","last_seen":"2019-01-14"},{"type":"issuer","type_label":"ISSUER","cik":"0001069530","name":"PAIN THERAPEUTICS INC","url":"/issuer/0001069530","role":"Ten percent owner","n_filings":2,"first_seen":"2018-08-20","last_seen":"2018-10-05"},{"type":"issuer","type_label":"ISSUER","cik":"0001267602","name":"ALIMERA SCIENCES INC","url":"/issuer/0001267602","role":"Ten percent owner","n_filings":1,"first_seen":"2018-02-09","last_seen":"2018-02-09"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001706140","retrieved_at":"2026-08-22T09:53:38+00:00","coverage":{"filings":1505395,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}